IMNN-001 improves median OS by over 14 months in newly diagnosed advanced ovarian cancer, phase II study shows

Ovarian Cancer Research Alliance launches a global AI-powered ecosystem to accelerate gynecologic cancer research

Ovarian Cancer Research Alliance announced the launch of the Community Accelerated Research Exchange, a first-of-its-kind, global, AI-powered ecosystem designed to transform how gynecologic cancer research is conducted—accelerating breakthroughs by connecting patients, clinicians, researchers, and advocates in real time.

May 15, 2026

Vol.52 No.19

In Brief

Mount Sinai and Cancer Hope Network launch peer support program to help patients navigate treatment, survivorship, and clinical trials

The Mount Sinai Tisch Cancer Center has entered a partnership with Cancer Hope Network to launch Peer Access to Trials, Hope and Support, a peer-to-peer program that gives patients and caregivers access to one-on-one peer mentorship from trained volunteers who have faced cancer themselves, either as survivors or caregivers.

May 15, 2026

Vol.52 No.19

In Brief

LSU LCMC Health cancer center strengthens cancer clinical trials infrastructure to expand access across Louisiana

The LSU LCMC Health Cancer Center expanded its Cancer Clinical Trials Office.

May 15, 2026

Vol.52 No.19

Clinical Roundup

65% of eligible lung cancer patients do not receive the most appropriate targeted therapies

Diaceutics has released research revealing a critical shift in precision medicine. Despite major advances in biomarker testing, nearly two-thirds of eligible patients with advanced non-small cell lung cancer in the U.S. are still not receiving the most appropriate treatment.

May 01, 2026

Vol.52 No.17

Clinical Roundup

Eating primes immune cells for future responses, UPMC study finds

Eating creates a temporary metabolic state that influences the function of T cells, according to researchers at the University of Pittsburgh.

May 01, 2026

Vol.52 No.17

Clinical Roundup

CAR T-cell therapy for high-risk smoldering MM shows deep and lasting responses in phase II study

In the phase II CAR-PRISM (PRecision Intervention Smoldering Myeloma) clinical trial, the first to investigate CAR T-cell therapy in patients with high-risk smoldering multiple myeloma, all 20 patients were negative for minimal residual disease within two months of treatment and remained MRD-negative after a median of 15.3 months of follow-up.

April 24, 2026

Vol.52 No.16

IMNN-001 improves median OS by over 14 months in newly diagnosed advanced ovarian cancer, phase II study shows

YOU MAY BE INTERESTED IN

Ovarian Cancer Research Alliance launches a global AI-powered ecosystem to accelerate gynecologic cancer research

Mount Sinai and Cancer Hope Network launch peer support program to help patients navigate treatment, survivorship, and clinical trials

LSU LCMC Health cancer center strengthens cancer clinical trials infrastructure to expand access across Louisiana

65% of eligible lung cancer patients do not receive the most appropriate targeted therapies

Eating primes immune cells for future responses, UPMC study finds

CAR T-cell therapy for high-risk smoldering MM shows deep and lasting responses in phase II study

Renew today!

Subscriber content

Never miss an issue!

Login